Tseng, Ping-TaoPing-TaoTsengZeng, Bing-SyuanBing-SyuanZengThompson, TrevorTrevorThompsonStubbs, BrendonBrendonStubbsPO-REN HSUEHSu, Kuan-PinKuan-PinSuChen, Yen-WenYen-WenChenChen, Tien-YuTien-YuChenWu, Yi-ChengYi-ChengWuLin, Pao-YenPao-YenLinCarvalho, Andre FAndre FCarvalhoHsu, Chih-WeiChih-WeiHsuLi, Dian-JengDian-JengLiYeh, Ta-ChuanTa-ChuanYehSun, Cheuk-KwanCheuk-KwanSunCheng, Yu-ShianYu-ShianChengShiue, Yow-LingYow-LingShiueLiang, Chih-SungChih-SungLiangYU-KANG TU2023-11-162023-11-162023-08-3013231316https://scholars.lib.ntu.edu.tw/handle/123456789/637166Many randomized controlled trials (RCTs) have investigated the use of interleukin 6 antagonists for the treatment of coronavirus disease 2019 (COVID-19), yielding inconsistent results. This network meta-analysis (NMA) aimed to identify the source of these inconsistent results by reassessing whether participants treated with standard of care (SoC) plus placebo have different all-cause mortality from those treated with SoC alone and to reevaluate the efficacy of interleukin 6 antagonists in the treatment of COVID-19.enCOVID-19; coronavirus disease 2019; interleukin 6; network meta-analysis; placebo effect[SDGs]SDG3Placebo effects on all-cause mortality of patients with COVID-19 in randomized controlled trials of interleukin 6 antagonists: A systematic review and network meta-analysisjournal article10.1111/pcn.13592376462042-s2.0-85172690945https://api.elsevier.com/content/abstract/scopus_id/85172690945